Emylcamate

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.

Emylcamate
Clinical data
ATC code
Identifiers
IUPAC name
  • 3-methyl-3-pentanol carbamate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.001.002
Chemical and physical data
FormulaC7H15NO2
Molar mass145.202 g·mol−1
3D model (JSmol)
SMILES
  • O=C(OC(C)(CC)CC)N
InChI
  • InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9) Y
  • Key:SLWGJZPKHAXZQL-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

MeprobamateEmylcamateEffect
175123 ED50 (mg/kg)
600550 LD50 (mg/kg)
3.44.4Therapeutic index

Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35. [1]

References
  1. Melander B (1959). "Emylcamate, A Potent Tranquillizing Relaxant". Journal of Medicinal and Pharmaceutical Chemistry. 1 (5): 443–457. doi:10.1021/jm50006a003.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.